Excelsior Medical Co., Ltd. · TWSE:4104
Excelsior Medical — Investor Conference 2024/5/27
16 slides from Excelsior Medical's conference presentation, May 27, 2024
Slide 1: Excelsior Medical Co., Ltd. Investor Conference
Excelsior Medical Co., Ltd. Investor Conference 2024/5/27
Slide 2: Disclaimer
Disclaimer This presentation is prepared according to the audited or reviewed financial statements by CPA and the financial figures hereby are based on IFRS, please refer to the published financial statements for full content. The presentation may contain forward-looking information and may differ m
Slide 3: The Business Types
The Business Types Hemodialysis Aesthetic Medical Trading Business Medical Devices Medical Consumables Home Appliances Product Planning Sales Information Analysis Promotion Hemodialysis channel Pharma. Sales and Promotion Market Creative Aesthetic Medical channel Pharma. Distribution and Logistics M
Slide 4: Revenue structure
Revenue structure Excelsior yearly consolidated sales is more than NT $ 8.2 billion in 2023, the primary revenue comes from Excelsior (Hemodialysis), Dynamic (Aesthetic Medical), Arich (Pharmaceutical Logistics) and others. According to the company’s function, the business type can be characterized
Slide 5: Operating Overview
Operating Overview Unit: NTD in thousands 5
Slide 6: Investment Overview
Investment Overview Unit: NTD in thousands 6
Slide 7: Profit after Tax Overview
Profit after Tax Overview Unit: NTD in thousands/ EPS: NTD in Dollars 7
Slide 8: Strategies and Outlook
Strategies and Outlook Long-Term Planning Continuing to follow the Mid-Term Planning government’s “The New Southbound Policy” and ⚫Externally, the Company will enter the production and seek strategic partners, continue manufacturing industry by to expand medical channels. investing in a HD solution
Slide 9: Assets
Unit: In thousands NTD 2022年12月31日 2023年12月31日 2024年3月31日 Assets Current Assets: Cash and cash equivalents 2,506,995 2,614,786 2,898,852 Receivables 1,713,858 1,961,336 1,789,340 Other receivables 3,315,313 3,853,342 3,760,163 Inventories 1,161,088 1,247,430 1,339,070 Other current assets 831,163 1,
Slide 10: Liabilities and Equity
Unit: In thousands NTD 2022年12月31日 2023年12月31日 2024年3月31日 Liabilities Current Liabilities Short- term borrowings 535,134 1,134,887 712,312 Payables 1,000,392 974,726 1,125,197 Other payables 3,215,075 3,464,888 4,517,386 Other current liabilities 1,001,444 1,104,256 1,070,864 Total Current Liabiliti
Slide 11: Statement of Comprehensive Income
Statement of Comprehensive Income Unit: In thousands NTD 2022 2023 2024 Q1 Operating revenue 7,186,828 8,233,404 2,042,037 Operating costs 5,673,716 6,557,836 1,630,096 Gross Profit 1,513,112 1,675,568 411,941 Gross Margin 21.05% 20.35% 20.17% Operating expenses 906,500 972,688 246,424 Operating Inc
Slide 12: Cash Flows from Operating Activities
Unit: In thousands NTD 2022 2023 2024 Q1 Profit before tax 963,700 1,144,080 273,935 Adjustments (86,537) (164,775) (36,308) Cash Flows from Operating Activities Receivables (108,221) (244,183) 165,844 Other receivables (436,495) (542,241) 98,815 Inventories (312,958) (139,988) (131,753) Payables 52
Slide 13: Cash Flows from Investing Activities
Unit: In thousands NTD 2022 2023 2024 Q1 Cash Flows from Investing Activities Proceeds from disposal of financial assets at fair value through 130,914 108,434 - other comprehensive income Acquisition of financial assets at amortized cost (441,456) (658,219) (108,000) Proceeds from disposal of financ
Slide 14: Cash Flows from Financing Activities
Unit: In thousands NTD 2022 2023 2024 Q1 Cash Flows from Financing Activities Increase(decrease) in short- term borrowings 55,168 599,753 (422,575) Cash dividends paid (494,021) (540,953) - Acquisition of ownership interests in subsidiaries (11,294) - - Proceeds from disposal of ownership interests
Slide 15: Growing up with Long-term partners
Growing up with Long-term partners Excelsior has been operating for 30 years, accumulated core competitiveness with new ideas created, new models to integrate various professional medical fields. Excelsior will keep taking root in the Asia market, the business scope includes Taiwan, Hong Kong, China
Slide 16: Growing up with Long-term partners
Growing up with Long-term partners Excelsior has been operating for 30 years, accumulated core competitiveness with new ideas created, new models to integrate variously professional medical fields. Excelsior will keep take root in the Asia market, the business scope includes Taiwan, Hong Kong, China